We are live on ! Find out more
VERA icon

Vera Therapeutics
VERA

59 hedge funds and large institutions have $413M invested in Vera Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 13

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

7% more funds holding

Funds holding: 55 → 59 (+4)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2.53% less ownership

Funds ownership: 79.66% → 77.12% (-2.5%)

10% less capital invested

Capital invested by funds: $459M → $413M (-$46.5M)

Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
10
Increased
23
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$12.9M
2
LGM
Logos Global Management
California
+$5.16M
3
EP
Eversept Partners
New York
+$4.62M
4
Walleye Capital
Walleye Capital
New York
+$4.15M
5
OCA
Octagon Capital Advisors
New York
+$2.39M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$33.6M
2
VC
Vivo Capital
California
-$4.82M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.58M
4
KCM
Kynam Capital Management
New Jersey
-$2.3M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$1.98M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$49K +$33.7K +1,862 +277%
AB
52
Amalgamated Bank
New York
$43K – – –
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$20.1K – – –
UBS Group
54
UBS Group
Switzerland
$17.4K -$79.7K -4,401 -83%
TRCT
55
Tower Research Capital (TRC)
New York
$10K -$18.2K -1,004 -65%
AIP
56
Ameritas Investment Partners
Nebraska
$9.69K – – –
Citigroup
57
Citigroup
New York
$9.04K -$14.2K -783 -63%
Dimensional Fund Advisors
58
Dimensional Fund Advisors
Texas
$223 +$208K +11,498 New
RCM
59
RA Capital Management
Massachusetts
– -$33.6M -1,578,820 Closed
Point72 Asset Management
60
Point72 Asset Management
Connecticut
– -$2.58M -121,000 Closed
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
– -$110K -5,183 Closed
CSS
62
Cubist Systematic Strategies
Connecticut
– -$107K -5,000 Closed
SO
63
STRS Ohio
Ohio
– -$34K -1,600 Closed
Wells Fargo
64
Wells Fargo
California
– -$5K -231 Closed
Nisa Investment Advisors
65
Nisa Investment Advisors
Missouri
– +$308 +17 New
1 2
3

VERA Hedge Fund Activity: Q4 2022 in Review

59 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q4 2022, worth a combined $413M — down 10% from $459M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new VERA positions and 6 closed out — a net gain of 4 holders — while 23 added to existing stakes and 13 trimmed.

The largest buyer was Millennium Management, adding an estimated $12.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $33.6M sold.

  • 59 institutional investors held Vera Therapeutics (VERA) as of Q4 2022, up from 55 in Q3 2022.
  • Funds reported $413M of Vera Therapeutics stock for Q4 2022, down 10% quarter-over-quarter.
  • 10 funds opened new Vera Therapeutics positions in Q4 2022 and 6 closed out, a net change of +4 holders.
  • The largest Vera Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $12.9M added.
  • The largest Vera Therapeutics seller in Q4 2022 was RA Capital Management, an estimated $33.6M sold.

Based on aggregated 13F filings for Q4 2022.